A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 6, 2010, Pages 1051-1057

  Ko, Andrew H ^a   Venook, Alan P ^a   Bergsland, Emily K ^a   Kelley, R Kate ^a   Korn, W Michael ^a   Dito, Elizabeth ^a   Schillinger, Brian ^a   Scott, Janet ^a   Hwang, Jimmy ^a   Tempero, Margaret A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bevacizumab; Circulating endothelial cells; Erlotinib; Pancreatic cancer; Phase II; Refractory

Indexed keywords

BEVACIZUMAB; CA 19-9 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; ERLOTINIB; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ENDOTHELIUM CELL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HUMAN CELL; HYPERTENSION; INTERSTITIAL PNEUMONIA; INTESTINE PERFORATION; LUNG EMBOLISM; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS FISTULA; PANCREATICODUODENECTOMY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; SURVIVAL RATE; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TREATMENT OUTCOME;

EID: 78149406059     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1257-5     Document Type: Article

References (30)

1. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun 2009 Cancer statistics, 2009 CA Cancer J Clin 59 225 249 10.3322/caac.20006 19474385
2. V Heinemann S Boeck A Hinke R Labianca C Louvet 2008 Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer BMC Cancer 8 82 10.1186/1471-2407-8-82 18373843 (Pubitemid 351552578)
3. C Louvet R Labianca P Hammel, et al. 2005 Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 3509 3516 1:CAS:528:DC%2BD2MXlsVyhsrg%3D 10.1200/JCO.2005.06.023 15908661
4. V Heinemann D Quietzsch F Gieseler, et al. 2006 Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer J Clin Oncol 24 3946 3952 1:CAS:528:DC%2BD28Xps1Sit78%3D 10.1200/JCO.2005.05.1490 16921047 (Pubitemid 46630743)
5. MJ Moore D Goldstein J Hamm, et al. 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 1960 1966 1:CAS:528:DC%2BD2sXmvVWmsr0%3D 10.1200/JCO.2006.07. 9525 17452677 (Pubitemid 46972777)
6. R Herrmann G Bodoky T Ruhstaller, et al. 2007 Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group J Clin Oncol 25 2212 2217 1:CAS:528:DC%2BD2sXnsVShtbw%3D 10.1200/JCO.2006.09.0886 17538165 (Pubitemid 46954645)
7. Schrag D, Archer L, Wang X, Romanus D (2007) A patterns-of-care study of post-progression treatment among patients with advanced pancreas cancer after gemcitabine therapy on Cancer and Leukemia Group B study #80303. J Clin Oncol 25(Suppl): (abstract 4524)
8. Kindler HL, Niedzwiecki D, Hollis D et al (2007) A double-blind, placebo-controlled, randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: a preliminary analysis of Cancer and Leukemia Group B. J Clin Oncol 25(Suppl): (abstract 4508)
9. Vervenne W, Bennouna J, Humblet Y et al (2008) A randomized, double-blind, placebo controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab to erlotinib and gemcitabine in patients with metastatic pancreatic cancer. J Clin Oncol 26(Suppl): (abstract 4507)
10. F Ciardiello R Bianco V Damiano, et al. 2000 Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells Clin Cancer Res 6 3739 3747 1:CAS:528: DC%2BD3cXntFCitrk%3D 10999768
11. YD Jung PF Mansfield M Akagi, et al. 2002 Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model Eur J Cancer 38 1133 1140 1:CAS:528:DC%2BD38Xjtl2mt7c%3D 10.1016/S0959-8049(02) 00013-8 12008203 (Pubitemid 34468020)
12. RM Bukowski FF Kabbinavar RA Figlin, et al. 2007 Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer J Clin Oncol 25 4536 4541 1:CAS:528: DC%2BD2sXht1yhsr7J 10.1200/JCO.2007.11.5154 17876014 (Pubitemid 350035309)
13. EE Cohen DW Davis TG Karrison, et al. 2009 Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study Lancet Oncol 10 247 257 1:CAS:528:DC%2BD1MXisFWjtr8%3D 10.1016/S1470-2045(09)70002-6 19201650
14. MN Dickler HS Rugo CA Eberle, et al. 2008 A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer Clin Cancer Res 14 7878 7883 1:CAS:528:DC%2BD1cXhsVegt77J 10.1158/1078-0432.CCR-08- 0141 19047117
15. RS Herbst VJ O'Neill L Fehrenbacher, et al. 2007 Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer J Clin Oncol 25 4743 4750 1:CAS:528:DC%2BD2sXhtlCgsLnP 10.1200/JCO.2007.12.3026 17909199 (Pubitemid 350086476)
16. Pelzer U, Kubica K, Stieler J, Schwaner I (2008) A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26(Suppl): (abstract 4508)
17. F Ciardiello R Caputo V Damiano, et al. 2003 Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase Clin Cancer Res 9 1546 1556 1:CAS:528:DC%2BD3sXislerur8%3D 12684431
18. A Hirata S Ogawa T Kometani T Kuwano S Naito M Kuwano M Ono 2002 ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase Cancer Res 62 2554 2560 1:CAS:528: DC%2BD38XjtlGrsbc%3D 11980649
19. AM Petit J Rak MC Hung P Rockwell N Goldstein B Fendly RS Kerbel 1997 Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors Am J Pathol 151 1523 1530 1:CAS:528:DyaK1cXpt1Gn 9403702
20. HL Kindler G Friberg DA Singh, et al. 2005 Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer J Clin Oncol 23 8033 8040 1:CAS:528:DC%2BD2MXht1CqsL%2FE 10.1200/JCO.2005.01.9661 16258101 (Pubitemid 46657405)
21. O'Reilly EM, Niedzwiecki D, Hollis DR et al (2008) A phase II trial of sunitinib in previously-treated pancreas adenocarcinoma, CALGB 80603. J Clin Oncol 26(Suppl): (abstract 4515)
22. R Torrisi V Bagnardi A Cardillo, et al. 2008 Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity Br J Cancer 99 1564 1571 1:CAS:528:DC%2BD1cXhtlGrur3E 10.1038/sj.bjc.6604741 18941458
23. CG Willett DG Duda E di Tomaso, et al. 2009 Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study J Clin Oncol 27 3020 3026 1:CAS:528:DC%2BD1MXoslyisLY%3D 10.1200/JCO.2008.21.1771 19470921
24. H Oettle D Arnold M Esser D Huhn H Riess 2000 Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma Anticancer Drugs 11 635 638 1:CAS:528:DC%2BD3cXnsl2gsrg%3D 10.1097/00001813-200009000-00006 11081455
25. H Ulrich-Pur M Raderer G Verena Kornek, et al. 2003 Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma Br J Cancer 88 1180 1184 1:CAS:528: DC%2BD3sXivFShs7w%3D 10.1038/sj.bjc.6600883 12698181 (Pubitemid 36606330)
26. N Tsavaris C Kosmas H Skopelitis, et al. 2005 Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study Invest New Drugs 23 369 375 1:CAS:528:DC%2BD2MXmtVymtb4%3D 10.1007/s10637-005-1446-y 16012797 (Pubitemid 40980360)
27. HA Burris III S Rivkin R Reynolds, et al. 2005 Phase II trial of oral rubitecan in previously treated pancreatic cancer patients Oncologist 10 183 190 1:CAS:528:DC%2BD2MXjsFSnsbo%3D 10.1634/theoncologist.10-3-183 15793221 (Pubitemid 40463155)
28. S Boeck K Weigang-Kohler M Fuchs, et al. 2007 Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial Ann Oncol 18 745 751 1:STN:280: DC%2BD2s7os1Ghsw%3D%3D 10.1093/annonc/mdl463 17229775 (Pubitemid 46523280)
29. MH Kulke LS Blaszkowsky DP Ryan, et al. 2007 Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer J Clin Oncol 25 4787 4792 1:CAS:528:DC%2BD2sXhtlCgsLbO 10.1200/JCO.2007.11.8521 17947726 (Pubitemid 350086482)
30. AH Ko E Dito B Schillinger AP Venook EK Bergsland MA Tempero 2008 Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study Cancer Invest 26 47 52 1:CAS:528:DC%2BD1cXisFOktw%3D%3D 10.1080/07357900701681483 18181045